Conexeu Sciences, a preclinical developer of a regenerative tissue device for wound care and aesthetics, filed a resale prospectus with the SEC stating that it expects its common stock to begin trading on the Nasdaq on or about Thursday, May 21, 2026, in connection with its direct listing.
The Reno, NV-based company is registering 9.5 million shares that may be sold by the Registered Securityholders identified in the prospectus. Conexeu Sciences will not raise new capital in its listing. In March 2026, Conexeu Sciences sold 486,970 shares at a price of $4.00 per share for gross proceeds of $1,947,880 pursuant to a private placement; at that $4 share price, the company would be valued at $84 million, excluding potentially dilutive securities.
Conexeu states that it has developed a proprietary platform built around a patented device candidate; CXU Scaffold, an extra cellular matrix (ECM) scaffold designed to support the body's natural regenerative processes. This platform leverages a temperature-sensitive collagen-based solution that becomes a gel-like scaffold upon injection or application in the body, typically within about ten minutes. Conexeu claims that this scaffold supports cell growth, tissue integration, and faster healing. The company is conducting preclinical research for its device to be used as an injectable soft-tissue filler for facial indications, as well as wound care.
Conexeu Sciences was founded in 2022. It plans to list on the Nasdaq under the symbol CNXU. As a direct listing without a firm commitment underwritten offering, there are no underwriters on the deal; instead, H.C. Wainwright & Co. is serving as the company's financial advisor.
